论文部分内容阅读
子宫肌瘤是育龄期妇女最常见的良性肿瘤,发病机制尚不明确,但普遍认为其是一种激素依赖性肿瘤,与雌激素、孕激素密切相关。米非司酮是一种孕激素受体和糖皮质激素受体拮抗剂,已被广泛用于治疗子宫肌瘤,能缩小子宫肌瘤的体积,显著改善临床症状,获得良好的近期疗效,相关实验室研究显示米非司酮通过拮抗雌激素、孕激素,使Bcl-2表达减低,肿瘤坏死因子α(TNF-α)高表达,降低血管内皮生长因子(VEGF)的表达和对VEGFmRNA表达,抑制胰岛素样生长因子-1(IGF-1)的活性,发挥治疗子宫肌瘤的作用。就米非司酮在子宫肌瘤的临床应用、相关实验室研究等进行综述。
Uterine fibroids are the most common benign tumors in women of childbearing age, the pathogenesis is not yet clear, but it is generally believed that it is a hormone-dependent tumor, and estrogen and progesterone are closely related. Mifepristone is a progesterone receptor and glucocorticoid receptor antagonist, has been widely used in the treatment of uterine fibroids, can reduce the size of uterine fibroids, significantly improve clinical symptoms, access to good short-term efficacy, related to Laboratory studies have shown that mifepristone can decrease the expression of Bcl-2, increase the expression of tumor necrosis factor-alpha (TNF-α), decrease the expression of vascular endothelial growth factor (VEGF) and the expression of VEGF mRNA by antagonizing estrogen and progesterone, Inhibit insulin-like growth factor-1 (IGF-1) activity, play a role in the treatment of uterine fibroids. On the clinical application of mifepristone in uterine fibroids, related laboratory studies are reviewed.